Scientists demonstrate pre-clinical proof of concept for next-gen DNA delivery technology

Scientists from The Wistar Institute, the University of Pennsylvania, the Icahn School of Medicine at Mount Sinai, Saint Joseph’s University (Philadelphia, PA), and Inovio Pharmaceuticals (Plymouth Meeting, PA) have described a next-generation vaccination technology that combines plasmid DNA with a lipid nanoparticle delivery system. The team showed that these DNA lipid nanoparticles demonstrate a unique way of priming the immune system compared to mRNA and protein-in-adjuvant formulations and that these DNA lipid nanoparticles induced robust antibody and T-cell responses after a single dose. Importantly, these responses were durable, with memory responses in small animals persisting beyond a year after immunization.